These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27419150)

  • 1. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.
    Chu CE; Wu F; He X; Zhou K; Cheng Y; Cai W; Geng E; Volberding P; Tucker JD
    Open Forum Infect Dis; 2016 Apr; 3(2):ofw065. PubMed ID: 27419150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.
    Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A
    Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China.
    Chu CE; Wu F; He X; Ma Q; Cheng Y; Cai W; Volberding P; Tucker JD
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):78-84. PubMed ID: 25427547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patient and treatment provider perceptions.
    Ortiz-Paredes D; Amoako A; Lessard D; Engler K; Lebouché B; Klein MB
    Can Liver J; 2022; 5(2):124-143. PubMed ID: 35991485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study.
    Desai A; O'Neal L; Reinis K; Brown C; Stefanowicz M; Kuang A; Agrawal D; Bhavnani D; Mercer T
    Implement Sci Commun; 2023 Aug; 4(1):98. PubMed ID: 37592306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors associated with HIV and hepatitis C virus co-infection among people who inject drugs in Cambodia.
    Saing CH; Prem K; Uk P; Chhoun P; Chann N; Tuot S; Mun P; Yi S
    Int J Drug Policy; 2020 Oct; 86():102974. PubMed ID: 33068831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review.
    Yanes-Lane M; Dussault C; Linthwaite B; Cox J; Klein MB; Sebastiani G; Lebouché B; Kronfli N
    J Viral Hepat; 2020 Feb; 27(2):205-220. PubMed ID: 31638294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
    Boerekamps A; Newsum AM; Smit C; Arends JE; Richter C; Reiss P; Rijnders BJA; Brinkman K; van der Valk M;
    Clin Infect Dis; 2018 Apr; 66(9):1352-1359. PubMed ID: 29186365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.
    Rich ZC; Chu C; Mao J; Zhou K; Cai W; Ma Q; Volberding P; Tucker JD
    BMC Public Health; 2016 Sep; 16():994. PubMed ID: 27645935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study - a prospective single-arm intervention trial.
    Desai A; O'Neal L; Reinis K; Chang P; Brown C; Stefanowicz M; Kuang A; Agrawal D; Bhavnani D; Mercer T
    Pilot Feasibility Stud; 2023 May; 9(1):78. PubMed ID: 37158965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.
    Walsh N; Maher L
    Curr Opin HIV AIDS; 2012 Jul; 7(4):339-44. PubMed ID: 22498482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review.
    Socías ME; Karamouzian M; Parent S; Barletta J; Bird K; Ti L
    Int J Drug Policy; 2019 Oct; 72():146-159. PubMed ID: 31147142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "I'm obviously not dying so it's not something I need to sort out today": Considering hepatitis C treatment in the era of direct acting antivirals.
    Wright C; Cogger S; Hsieh K; Goutzamanis S; Hellard M; Higgs P
    Infect Dis Health; 2019 May; 24(2):58-66. PubMed ID: 30541692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs.
    Høj SB; Jacka B; Minoyan N; Artenie AA; Bruneau J
    Int J Drug Policy; 2019 Oct; 72():11-23. PubMed ID: 31003825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.